Ohcanbohtosat - Semiond, Dorothée

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors Dahkki Ferron, Géraldine M., Dai, Yang, Semiond, Dorothée

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Preclinical profile of cabazitaxel Dahkki Vrignaud, Patricia, Semiond, Dorothée, Benning, Veronique, Beys, Eric, Bouchard, Hervé, Gupta, Sunil

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood–brain barrier in mice and rats Dahkki Cisternino, Salvatore, Bourasset, Fanchon, Archimbaud, Yves, Sémiond, Dorothée, Sanderink, Gérard, Scherrmann, Jean-Michel

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours Dahkki Fumoleau, Pierre, Trigo, Jose Manuel, Isambert, Nicolas, Sémiond, Dorothée, Gupta, Sunil, Campone, Mario

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients Dahkki Fau, Jean‐Baptiste, El‐Cheikh, Raouf, Brillac, Claire, Koiwai, Kimiko, Mace, Nathalie, Campana, Frank, Semiond, Dorothee, Nguyen, Laurent

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone Dahkki Thai, Hoai‐Thu, Gaudel, Nadia, Cerou, Marc, Ayral, Geraldine, Fau, Jean‐Baptiste, Sebastien, Bernard, van de Velde, Helgi, Semiond, Dorothée, Veyrat‐Follet, Christine

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma Dahkki Mikhael, Joseph, Richardson, Paul, Usmani, Saad Z., Raje, Noopur, Bensinger, William, Karanes, Chatchada, Campana, Frank, Kanagavel, Dheepak, Dubin, Franck, Liu, Qianying, Semiond, Dorothée, Anderson, Kenneth

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma Dahkki Koiwai, Kimiko, El‐Cheikh, Raouf, Thai, Hoai‐Thu, Brillac, Claire, Fau, Jean‐Baptiste, Veyrat‐Follet, Christine, Risse, Marie‐Laure, van de Velde, Helgi, Semiond, Dorothée, Nguyen, Laurent

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myelom... Dahkki Rachedi, Fatiha, Koiwai, Kimiko, Gaudel‐Dedieu, Nadia, Sebastien, Bernard, Thai, Hoai‐Thu, Brillac, Claire, Fau, Jean Baptiste, Nguyen, Laurent, van de Velde, Helgi, Veyrat‐Follet, Christine, Semiond, Dorothée

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis Dahkki Dimopoulos, Meletios A., Leleu, Xavier, Moreau, Philippe, Richardson, Paul G., Liberati, Anna Marina, Harrison, Simon J., Miles Prince, H., Ocio, Enrique M., Assadourian, Sylvie, Campana, Frank, Malinge, Laure, Sémiond, Dorothée, van de Velde, Helgi, Yong, Kwee

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab Dahkki Mikhael, Joseph, Belhadj-Merzoug, Karim, Hulin, Cyrille, Vincent, Laure, Moreau, Philippe, Gasparetto, Cristina, Pour, Ludek, Spicka, Ivan, Vij, Ravi, Zonder, Jeffrey, Atanackovic, Djordje, Gabrail, Nashat, Martin, Thomas G., Perrot, Aurore, Bensfia, Samira, Weng, Qilong, Brillac, Claire, Semiond, Dorothée, Macé, Sandrine, Corzo, Kathryn P., Leleu, Xavier

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta